Abemaciclib + LY3214996
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma, GBM, Glioma
Trial Timeline
Jul 11, 2020 → Sep 3, 2025
NCT ID
NCT04391595About Abemaciclib + LY3214996
Abemaciclib + LY3214996 is a phase 1 stage product being developed by Eli Lilly for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04391595. Target conditions include Glioblastoma, GBM, Glioma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04534283 | Phase 2 | Terminated |
| NCT04391595 | Phase 1 | Completed |
Competing Products
20 competing products in Glioblastoma